Gene therapies should be for all
By Editorial,
Nature
| 08. 12. 2021
More than 200 phase 2 and 3 gene therapy trials are currently underway, which could translate into up to 40 new products’ being approved for clinical use in the next decade, and the potential eligibility of 1.09 million patients for this therapeutic modality in the next 15 years. The availability of more gene therapy products will bring profound changes to the treatment landscape of many rare genetic diseases, which will offer for the first time potentially curative options for patients. Healthcare systems worldwide have to start preparing now to cope with the challenge of ensuring that all patients, not just a select few with financial means and privileged access to technology, can benefit from these innovative therapies.
Cost is at the center of the gene therapy accessibility problem. In many countries, drug prices are regulated and subject to existing laws; however, for gene therapies, pricing remains largely unregulated and is decided on a case-by-case basis, often concentrating on a single upfront payment. When determining the price, drug companies consider development costs, the specific characteristics of the disease and the...
Related Articles
By Mary Annette Pember, ICT News [cites CGS' Katie Hasson] | 04.18.2025
The sight of a room full of human cadavers can be off-putting for some, but not for Haley Omeasoo.
In fact, Omeasoo’s comfort level and lack of squeamishness convinced her to pursue studies in forensics and how DNA can be...
Gray wolf by Jessica Eirich via Unsplash
“I’m not a scarcity guy, I’m an abundance guy”
– Colossal co-founder and CEO Ben Lamm, The New Yorker, 4/14/25
Even the most casual consumers of news will have seen the run of recent headlines featuring the company Colossal Biosciences. On March 4, they announced with great fanfare the world’s first-ever woolly mice, as a first step toward creating a woolly mammoth. Then they topped that on April 7 by unveiling one...
By Katrina Northrop, The Washington Post | 04.06.2025
photo via Wikimedia Commons licensed under CC by 3.0
China's most infamous scientist is attempting a comeback. He Jiankui, who went to jail for three years after claiming he had created the world's first genetically altered babies, says he remains...
By Anumita Kaur [cites CGS’ Katie Hasson], The Washington Post | 03.25.2025
Genetic information company 23andMe has said that it is headed to bankruptcy court, raising questions for what happens to the DNA shared by millions of people with the company via saliva test kits.
Sunday’s announcement clears the way for a new...